文献リスト

1) Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009; 50: 291-308

2) Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol. 2010; 52: 745-58

3) Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51: 2193-213

4) Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010; 139: 58-72 e4

5) Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51: 660-78

6) Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Dig Liver Dis. 2010; 42: 390-400

7) Invernizzi P, Selmi C, Gershwin ME. Update on primary biliary cirrhosis. Dig Liver Dis. 2010; 42: 401-8

8) Karlsen TH, Melum E, Franke A. The utility of genome-wide association studies in hepatology. Hepatology. 2010; 51: 1833-42

9) Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009; 360: 2544-5

10) Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010; 42: 655-7

11) Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010; 42: 658-60

12) Yoshida K, Yang GX, Zhang W, et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology. 2009; 50: 1494-500

13) Corpechot C, Chretien Y, Chazouilleres O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010; 53: 162-9

14) Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut. 2010; 59: 508-12

15) Shimoda S, Miyakawa H, Nakamura M, et al. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J Autoimmun. 2008; 31: 110-5

16) Sasaki M, Ikeda H, Yamaguchi J, et al. Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing cellular senescence. Hepatology. 2008; 48: 186-95

17) Sasaki M, Miyakoshi M, Sato Y, et al. Autophagy mediates the process of cellular senescence characterizing bile duct damages in primary biliary cirrhosis. Lab Invest. 2010; 90: 835-43

18) Sasaki M, Miyakoshi M, Sato Y, et al. Modulation of the microenvironment by senescent biliary epithelial cells may be involved in the pathogenesis of primary biliary cirrhosis. J Hepatol. 2010; 53: 318-25

19) Shimoda S, Harada K, Niiro H, et al. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology. 2010; 51: 567-75

20) Shimoda S, Harada K, Niiro H, et al. Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells. Hepatology. 2008; 47: 958-65

21) Lleo A, Selmi C, Invernizzi P, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009; 49: 871-9

22) Lleo A, Bowlus CL, Yang GX, et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology. 2010; 52: 987-98

23) Nakanuma Y, Zen Y, Harada K, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int. 2010; 60: 167-74

24) Huet PM, Vincent C, Deslaurier J, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology. 2008; 135: 1552-60

25) Solaymani-Dodaran M, Aithal GP, Card T, et al. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol. 2008; 103: 2784-8

26) 廣原淳子. 原発性胆汁性肝硬変全国調査(第29報). 厚生労働科学研究補助金(難治性疾患克服研究事業)難治性の肝・胆道疾患に関する調査研究平成20年度総括・分担研究報告書. 2009. p.53-5

27) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51: 237-67

28) Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008; 48: 871-7

29) Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006; 130: 715-20

30) Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009; 136: 1281-7

31) Ohishi Y, Nakamura M, Iio N, et al. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology. 2008; 48: 853-62

32) Manousou P, Arvaniti V, Tsochatzis E, et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl. 2010; 16: 64-73

33) Silveira MG, Talwalkar JA, Lindor KD, et al. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2010; 10: 720-6

34) Kido M, Watanabe N, Okazaki T, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology. 2008; 135: 1333-43

35) Lapierre P, Beland K, Martin C, et al. Forkhead box p3＋ regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis. Hepatology. 2010; 51: 1789-98

36) Zierden M, Odenthal EK, Dienes HP. Effects and regulation of autoreactive CD8(＋) T cells in a transgenic mouse model of autoimmune hepatitis. Gastroenterology. 2010; 139: 975-86

37) Kruse N, Neumann K, Schrage A, et al. Priming of CD4＋ T cells by liver sinusoidal endothelial cells induces CD25low forkhead box protein 3- regulatory T cells suppressing autoimmune hepatitis. Hepatology. 2009; 50: 1904-3

38) Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008; 48: 169-76

39) Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008; 48: 1540-8

40) Gatselis NK, Zachou K, Papamichalis P, et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score？ Dig Liver Dis. 2010; 42: 807-12

41) Miyake Y, Iwasaki Y, Kobashi H, et al. Clinical features of autoimmune hepatitis diagnosed based on simplified criteria of the International Autoimmune Hepatitis Group. Dig Liver Dis. 2010; 42: 210-5

42) Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology. 2009; 50: 538-45

43) Umemura T, Zen Y, Hamano H, et al. IgG4 associated autoimmune hepatitis: a differential diagnosis for classical autoimmune hepatitis. Gut. 2007; 56: 1471-2

44) Chung H, Watanabe T, Kudo M, et al. Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int. 2010; 30: 222-31

45) Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010; 51: 2040-8

46) 恩地森一. 自己免疫性肝炎の全国調査(第一報). 厚生労働科学研究補助金(難治性疾患克服研究事業)難治性の肝・胆道疾患に関する調査研究平成21年度総括・分担研究報告書. 2010. p.21-2

47) Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010; 53: 191-8

48) Miyake Y, Iwasaki Y, Kobashi H, et al. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int. 2009, epub ahead of print

49) Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis. 2009; 29: 273-85

50) Manns MP, Woynarowski M, Kreisel W, et al. Azathioprine with budesonide induces remission more effectively than with prednisone in patients with autoimmune hepatitis. Gastroenterology. 2010, epub ahead of print

51) Beuers U. Hepatic overlap syndromes. J Hepatol. 2005; 42 Suppl: S93-9

52) Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007; 102: 1244-50

53) Yokokawa J, Saito H, Kanno Y, et al. Overlap of primary biliary cirrhosis and autoimmune hepatitis: Characteristics, therapy, and long term outcomes. J Gastroenterol Hepatol. 2010; 25: 376-82

54) Chazouilleres O, Wendum D, Serfety L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998; 28: 296-301

55) Chazouilleres O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006; 44: 400-6

56) Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002; 35: 409-13

57) Muratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009; 104: 1420-5

58) Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010; 138: 1102-1

59) Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis. Semin Immunopathol. 2009; 31: 383-97

60) Weber C, Kuhlencordt R, Grotelueschen R, et al. Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis. Endoscopy. 2008; 40: 739-45

61) Chavhan GB, Roberts E, Moineddin R, et al. Primary sclerosing cholangitis in children: utility of magnetic resonance cholangiopancreatography. Pediatr Radiol. 2008; 38: 868-73

62) Bjornsson E, Chari ST, Smyrk TC, et al. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007; 45: 1547-4

63) Webster GJ, Pereira SP, Chapman RW. Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis-overlapping or separate diseases？ J Hepatol. 2009; 51: 398-402

64) Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology. 2010; 51: 174-80

65) Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008; 48: 1106-7

66) Tanaka A, Takamori Y, Toda G, et al. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int. 2008; 28: 983-9

67) Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009; 50: 158-64

68) Shi J, Li Z, Zeng X, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res. 2009; 39: 865-73

69) Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009; 50: 808-14

70) Giljaca V, Poropat G, Stimac D, et al. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2010: CD004036

71) Mizuno S, Hirano K, Tada M, et al. Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol. 2010; 45: 758-62

72) 江川裕人. 原発性硬化性胆管炎肝移植後長期成績に関する全国多施設共同研究. 厚生労働科学研究補助金(難治性疾患克服研究事業)難治性の肝・胆道疾患に関する調査研究平成21年度総括・分担研究報告書. 2010. p.87

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp